| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. | 20% | $35,980,809 | 14,110,121 | Oramed Pharmaceuticals Inc. | 24 Apr 2025 | |||
| Sofer Uzi | 16% | $37,818,516 | 13,702,361 | Uzi Sofer | 31 Dec 2022 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (% of par) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 1,832,497 | $8,263,970 | +$1,145,345 | 451% | 31 |
| 2025 Q2 | 1,586,693 | $4,950,874 | +$1,313,729 | 312% | 24 |
| 2025 Q1 | 1,172,124 | $2,940,869 | +$461,245 | 251% | 23 |
| 2024 Q4 | 976,001 | $3,025,475 | +$134,426 | 310% | 21 |
| 2024 Q3 | 948,076 | $2,228,639 | -$143,072 | 238% | 23 |
| 2024 Q2 | 1,296,861 | $3,253,557 | -$610,750 | 253% | 24 |
| 2024 Q1 | 355,626 | $1,015,675 | -$71,635 | 295% | 5 |
| 2023 Q4 | 1,840,525 | $5,505,585 | +$1,681,256 | 301% | 26 |
| 2023 Q3 | 975,005 | $3,652,424 | +$100,189 | 379% | 23 |
| 2023 Q2 | 932,296 | $4,074,257 | +$2,059,369 | 437% | 18 |
| 2023 Q1 | 652,086 | $1,871,091 | +$336,132 | 287% | 16 |
| 2022 Q4 | 533,823 | $1,697,581 | -$884,134 | 318% | 13 |
| 2022 Q3 | 686,488 | $4,006,000 | -$9,740 | 584.01% | 15 |
| 2022 Q2 | 653,675 | $5,920,000 | +$1,784,954 | 900.91% | 13 |
| 2022 Q1 | 447,472 | $5,281,000 | +$5,281,007 | 1,180.75% | 11 |